

Pharma in brief - Canada

Health Canada releases for consultation Draft Guidance Document – Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs

Summary

Health Canada recently released for consultation the Draft Guidance Document – Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs. Stakeholders may provide comments on the draft guidance document by email to Policy_Bureau_Enquiries@hc-sc.gc.ca. The consultation period is open until **April 18, 2017**.

Overview

The draft guidance document outlines the conditions and procedures by which Health Canada administratively processes a change in manufacturer name and/or product name as a result of business circumstances (such as licensing arrangements or mergers/buyouts), when there are no deviations to the product.

Once finalized, this guidance document will replace Health Canada's policy [Change in Manufacturer's / Product Name Policy](#), which currently governs the administrative processing of drug submissions and applications.

The draft guidance document addresses current policy gaps that have been identified and provides clarity to industry on the requirements under this administrative pathway.

Generally, the types of applications that will be eligible for administrative processing include:

- manufacturer name change
- product name change
- product ownership change (i.e., change in DIN holder)
- merger or buyout
- additional product name
- licensing agreement between two manufacturers (this policy does not govern secondary licensing agreements between licensees and third parties)
- revised/updated product monograph

This draft guidance document provides additional information about the roles and responsibilities of manufacturers, licensors and licensees, as well as the types of documentation and attestations required upon submission.

The draft also sets out some expectations on labelling considerations, including a six-month phased-in period to replace original product labels with new product labels for manufacturers transitioning their products under new business arrangements.

Link:**[Draft Guidance Document: Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs](#)**

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For a complete list of our IP team, [click here](#). For a complete list of our Life sciences and healthcare team, [click here](#).

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to "Norton Rose Fulbright", "the law firm", and "legal practice" are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together "Norton Rose Fulbright entity/entities"). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a "partner") accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.